Zimmer Biomet Stock Price, News & Analysis

Zimmer Biomet (NYSE: ZBH) and OneStep announced an exclusive collaboration to integrate OneStep's clinically validated mobility intelligence into Zimmer Biomet's mymobility Care Management Platform for joint replacement patients, effective Dec 16, 2025.

The integration will feed smartphone-based gait and functional mobility analytics (iPhone and Android) directly into mymobility to support remote assessment, patient engagement, and clinician-tailored rehabilitation. OneStep processes more than one million gait cycles every day, providing a large real-world mobility dataset to quantify recovery trends and functional outcomes.

Zimmer Biomet (NYSE: ZBH) announced U.S. FDA 510(k) clearance of ROSA® Knee with OptimiZe™, an enhanced version of its ROSA Knee robotic system for total knee replacement surgery.

The update adds five OptimiZe features—Planning, Landmarking, Tracking, Kinematic Alignment and Experience—plus integration with ZBEdge® Analytics. The company said OptimiZe Planning™ can reduce planning time by an average of 46%. Zimmer Biomet plans a targeted release later in 2025 and expects U.S. commercial availability in Q1 2026.

Zimmer Biomet (NYSE: ZBH) said members of its management team will present at the Annual Jefferies Global Healthcare Conference in London on Tuesday, Nov. 18, 2025 at Noon GMT (7 a.m. ET). A live webcast will be available on the company's investor relations website and will be archived for replay after the conference.

Zimmer Biomet (NYSE: ZBH) reported third quarter 2025 results on November 5, 2025: net sales $2.001B, up 9.7% reported, 8.6% on a constant currency basis and 5.0% on an organic constant currency basis. Net earnings $230.9M and adjusted diluted EPS $1.90 (+9.2%). The company completed the acquisition of Monogram Technologies and closed the April Paragon 28 acquisition, expanding robotics and extremities portfolios. Japan PMDA approval was received for the iodine-treated iTaperloc Complete and iG7 Hip System. Full-year 2025 reported revenue and adjusted EPS guidance are maintained while constant-currency revenue ranges were narrowed.

Zimmer Biomet (NYSE: ZBH) announced the FDA granted Breakthrough Device Designation for its iodine-treated total hip replacement system on October 28, 2025. This is the first time the company has received this designation. The system integrates controlled-release Iodine Technology into the iTaperloc Complete and iG7 Hip System to help address periprosthetic joint infections (PJI). The device received PMDA approval in Japan in September 2025 as the world’s first approved orthopedic implant with this iodine treatment. The FDA program offers prioritized review and earlier agency interaction during regulatory review.

Zimmer Biomet (NYSE: ZBH) is showcasing robotics and musculoskeletal product innovations at the 2025 AAHKS Annual Meeting on Oct. 21, 2025. Highlights include the mBôs TKA System (CT-based, semi-autonomous) with U.S. FDA 510(k) clearance and a surgeon-guided autonomous version in clinical trials, the recently acquired Monogram surgeon-guided technology, and the ROSA Knee with OptimiZe pending FDA 510(k) clearance.

Other exhibits: TMINI miniature robotic system, ZBEdge analytics, mymobility care platform, Persona and Oxford knee technologies, Persona IQ smart knee, and multiple hip reconstruction tools.

Zimmer Biomet (NYSE: ZBH) launched two foot and ankle trauma implants on Oct 8, 2025: the Gorilla Pilon Fusion Plating System and the Phantom TTC Trauma Nail. Both products target complex pilon fractures and hindfoot injuries and are available to U.S. foot and ankle specialists.

The Gorilla system provides anatomically contoured dual-column plates, Type II anodized construction, percutaneous guides and long-shaft designs for primary tibiotalar fusion in severely comminuted pilon cases. The Phantom TTC Trauma Nail adds 150/300/350 mm lengths, PRECISION guide technology, up to 8 mm internal compression and Ø7.2/Ø5.0 threaded pegs.

Zimmer Biomet (NYSE: ZBH) completed its acquisition of Monogram Technologies on Oct 7, 2025, adding Monogram's AI-driven semi- and fully autonomous orthopedic robotics to Zimmer Biomet's robotics and navigation portfolio.

Deal consideration converted each Monogram share into $4.04 cash plus non-tradeable contingent value rights (CVRs) entitling holders to up to $12.37 in cash if specified product, regulatory, and revenue milestones are met through 2030. Monogram received FDA 510(k) clearance in March 2025 for a CT-based semi-autonomous TKA system, with commercialization targeted with Zimmer Biomet implants by early 2027. Monogram began a clinical study for a fully autonomous version in July 2025. Zimmer Biomet's ROSA platform is approaching 2,000 installations worldwide and ROSA Knee with OptimiZe has been submitted to the FDA with 510(k) anticipated later in 2025.

Zimmer Biomet (NYSE: ZBH) announced its Q3 2025 earnings webcast and conference call on Wednesday, November 5, 2025 at 8:30 a.m. ET. A news release with the quarterly results will be published the same day at 6:30 a.m. ET. The live audio webcast will be available on Zimmer Biomet's Investor Relations website at https://investor.zimmerbiomet.com and will be available for replay after the call.

U.S. and Canada dial-in: (800) 330-6710 with conference ID 7090861. International dial-in: +1 (213) 279-1505 with conference ID 7090861.